Neopterin production, tryptophan degradation, and mental depression - What is the link?

被引:202
作者
Widner, B
Laich, A
Sperner-Unterweger, B
Ledochowski, M
Fuchs, D
机构
[1] Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Dept Med Nutr, A-6020 Innsbruck, Austria
[3] Univ Innsbruck, Ludwig Boltzmann Inst AIDS Res, A-6020 Innsbruck, Austria
[4] Univ Innsbruck, Dept Psychiat, A-6020 Innsbruck, Austria
关键词
depression; immune activation; indoleamine (2,3)-dioxygenase; interferon-gamma; kynurenine; neopterin; tryptophan;
D O I
10.1016/S0889-1591(02)00006-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The cytokine interferon-gamma stimulates human monocytes/macrophages to release large amounts of neopterin. Increased neopterin concentrations in body fluids of patients are observed during diseases with activated cellular (=TH1-type) immune response such as allograft rejection, virus infections, autoimmune disorders, or malignant tumors but also in neurodegenerative diseases or during pregnancy. In various cells interferon-gamma induces indoleamine 2,3-dioxygenase (IDO) which degrades tryptophan via the kynurenine pathway. Therefore like increased neopterin formation, enhanced tryptophan degradation is observed in diseases concomitant with cellular immune activation. Disturbed metabolism of tryptophan affects biosynthesis of neuro transmitter 5-hydroxytryptamine (serotonin), and it appears to be associated with an increased susceptibility for depression. In fact, enhanced neopterin concentrations together with increased degradation of tryptophan and low serum levels of tryptophan correlate with neuropsychiatric abnormalities like cognitive decline and depressive symptoms especially in long-lasting and chronic diseases. Activation of IDO could represent an important link between the immunological network and the pathogenesis of depression. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:590 / 595
页数:6
相关论文
共 42 条
  • [41] Widner Bernhard, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P251
  • [42] Advanced oxidation protein products as a novel marker of oxidative stress in uremia
    WitkoSarsat, V
    Friedlander, M
    CapeillereBlandin, C
    NguyenKhoa, T
    Nguyen, NT
    Zingraff, J
    Jungers, P
    DescampsLatscha, B
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (05) : 1304 - 1313